Xuesaitong exerts long-term neuroprotection for stroke recovery by inhibiting the ROCKII pathway, in vitro and in vivo

Zhou, Dongrui; Cen, Kai; Liu, Wei; Liu, Fengzhi; Liu, Ruijia; Sun, Yikun; Zhao, Yizhou; Chang, Jingling; Zhu, Li

doi:10.1016/j.jep.2021.113943

Cited by 19 publications

(11 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to previous research results, a clinical study of 204 patients with acute cerebral infarction (27) that used internationally recognized neurological defect score changes and clinical efficacy as the observation indicators showed that the total efficacy of patients with acute cerebral infarction in the Xuesaitong treatment group after 8 weeks of treatment was significantly higher than that of the conventional treatment group. For patients with acute cerebral infarction, Xuesaitong improves clinical efficacy, possibly by inhibiting the calcium load of brain cells (28), stabilizing cell membranes, protecting reperfusion injury caused by ischemia, reducing platelet aggregation, and reducing brain cell oxygen consumption (29).…”

Section: Discussionmentioning

confidence: 99%

The efficacy and safety of the Xuesaitong soft capsule in the treatment of patients with ischemic stroke: systematic review and meta-analysis

Gao¹,

Chen²,

Li³

et al. 2022

Ann Palliat Med

View full text Add to dashboard Cite

Background: Ischaemic stroke is a common neurological disease and a leading cause of severe disability and death in developed countries. In most cases, stroke is thought to be a multifactorial disorder or complex trait for which classic patterns of inheritance cannot be shown. Xuesaitong is one of the most commonly used medicines for treating ischemic stroke in China. However, compared to the conventional therapy, the effectiveness and safety of Xuesaitong for ischemic stroke needs to be further systematically reviewed and determined.Methods: Relevant randomized controlled trials (RCTs) examining the use of the Xuesaitong soft capsule in the treatment of patients with ischemic stroke were identified from databases, including the China National Knowledge Infrastructure, Wanfang, PubMed, Embase, and Web of Science databases. Next, 2 researchers independently extracted information from the included studies, analyzed the data using STATA 15.0 software, and evaluated the quality of the included studies using RevMan 5.3.Results: A total of 17 RCTs (comprising 1,942 patients with ischemic stroke) were included in the metaanalysis. The meta-analysis results showed that the Xuesaitong soft capsule treatment increased patients' total effective rate compared to conventional or other drug treatments, and improved patients' Clinical Severity Score (CSS scores) or Barthel index (BI) score. A further subgroup analysis stratified by different treatment times showed that Xuesaitong soft capsule treatment at 4 and 8 weeks improved CSS scores more than treatment at 2 weeks in patients with ischemic stroke. Additionally, the Xuesaitong soft capsule also significantly improved plasma viscosity, whole-blood viscosity at high and low shear rates, fibrinogen, hematocrit, and the effect on traditional Chinese medicine (TCM) single symptoms or signs in patients with ischemic stroke.Discussion: In summary, compared to conventional or other drug treatments, the Xuesaitong soft capsule treatment was beneficial in improving patients' TCM symptoms (e.g., crooked mouth and tongue, and dizziness) and various indicators. Further, Xuesaitong soft capsule may be a safe and effective drug for the treatment of ischemic stroke. And large-scale randomized clinical trials are needed to further confirm our findings.

show abstract

Section: Discussionmentioning

confidence: 99%

The efficacy and safety of the Xuesaitong soft capsule in the treatment of patients with ischemic stroke: systematic review and meta-analysis

Gao¹,

Chen²,

Li³

et al. 2022

Ann Palliat Med

View full text Add to dashboard Cite

show abstract

“…Xue Sai Tong Injection (XSTI) is also a classic CHM injection; its main constituent is saponins, which are extracted from Panax notoginseng (Burkill) F.H.Chen [Araliaceae; Notoginseng radix et rhizoma]. The research finds that XSTI reduces neurological dysfunction and pathological damage, promotes weight gain and synaptic regeneration, and reduces Nogo-A mRNA and protein levels by inhibiting the ROCKII pathway in models of MCAO-induced rats and OGD/R-induced SH-SY5Y cells ( Zhou et al, 2021 ).…”

Section: Chm Preparations For Ci/rimentioning

confidence: 99%

Recent Advances in Chinese Herbal Medicine for Cerebral Ischemic Reperfusion Injury

et al. 2022

View full text Add to dashboard Cite

Cerebral ischemic reperfusion injury (CI/RI) is a critical factor that leads to a poor prognosis in patients with ischemic stroke. It is an extremely complicated pathological process that is clinically characterized by high rates of disability and mortality. Current available treatments for CI/RI, including mechanical and drug therapies, are often accompanied by significant side effects. Therefore, it is necessary to discovery new strategies for treating CI/RI. Many studies confirm that Chinese herbal medicine (CHM) was used as a potential drug for treatment of CI/RI with the advantages of abundant resources, good efficacy, and few side effects. In this paper, we investigate the latest drug discoveries and advancements on CI/RI, make an overview of relevant CHM, and systematically summarize the pathophysiology of CI/RI. In addition, the protective effect and mechanism of related CHM, which includes extraction of single CHM and CHM formulation and preparation, are discussed. Moreover, an outline of the limitations of CHM and the challenges we faced are also presented. This review will be helpful for researchers further propelling the advancement of drugs and supplying more knowledge to support the application of previous discoveries in clinical drug applications against CI/RI.

show abstract

“…(rhizome), berberine promoted wound healing in both type I diabetes and type II diabetes, which decreased oxidative damage, cell apoptosis, and ECM remodeling through thioredoxin reductase 1/c-Jun N-terminal kinase (TrxR1/JNK) signaling [21,22]. Panax notoginseng and its main bioactive components exhibit pharmacological activity in various diseases, such as cancer, hypoglycemic effects, neuroprotection, and diabetes complications [23][24][25]. As one of the most important active components extracted from Panax notoginseng Notoginsenoside R1 (NR1) [26], it demonstrated an effective effect on various diabetic complications including diabetic nephropathy [27] and diabetic encephalopathy [28].…”

Section: Introductionmentioning

confidence: 99%

Notoginsenoside R1 Facilitated Wound Healing in High-Fat Diet/Streptozotocin-Induced Diabetic Rats

Cao

Xiang

Zhou

et al. 2022

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Diabetic ulcers bring about high morbidity and mortality in patients and cause a great economic burden to society as a whole. Since existing treatments cannot fulfil patient requirements, it is urgent to find effective therapies. In this study, the wound healing effect of topical notoginsenoside R1 (NR1) treatment on diabetic full-thickness wounds in type II diabetes mellitus (T2DM) was induced by the combination of a high-fat diet and streptozotocin (STZ) injection. NR1 significantly increased the wound closure rate, enhanced extracellular matrix (ECM) secretion, promoted collagen growth, increased platelet endothelial cell adhesion molecule-1 (CD31) expression, and decreased cleaved caspase-3 expression. RNA-Seq analysis identified ECM remodeling and inflammation as critical biological processes and Timp1 and Mmp3 as important targets in NR1-mediated wound healing. Further experiments showed that NR1-treated wounds demonstrated higher expression of tissue inhibitor of metalloproteinase 1 (TIMP1) and transforming growth factor-β1 (TGFβ1) and lower expression of matrix metallopeptidase 9 (MMP9), matrix metallopeptidase 3 (MMP3), interleukin-1β (IL-1β), and interleukin-6 (IL-6) than diabetic wounds. These investigations promote the understanding of the mechanism of NR1-mediated diabetic wound healing and provide a promising therapeutic drug to enhance diabetic wound healing.

show abstract

Xuesaitong exerts long-term neuroprotection for stroke recovery by inhibiting the ROCKII pathway, in vitro and in vivo

Cited by 19 publications

References 79 publications

The efficacy and safety of the Xuesaitong soft capsule in the treatment of patients with ischemic stroke: systematic review and meta-analysis

The efficacy and safety of the Xuesaitong soft capsule in the treatment of patients with ischemic stroke: systematic review and meta-analysis

Recent Advances in Chinese Herbal Medicine for Cerebral Ischemic Reperfusion Injury

Notoginsenoside R1 Facilitated Wound Healing in High-Fat Diet/Streptozotocin-Induced Diabetic Rats

Contact Info

Product

Resources

About